Skip to main content

AEON Biopharma, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

AEON$0.18-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert Bancroft as such individual’s true and lawful attorney in fact and agent with full power of substitution, for such individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual’s substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​​​​​
Signature​Title​Date
​​​
/s/ Robert Bancroft​President, Chief Executive Officer​March 30, 2026
Robert Bancroft​(Principal Executive Officer)​
​​​​​
/s/ Jennifer Sy​Chief Accounting Officer​March 30, 2026
Jennifer Sy​(Principal Financial and Accounting Officer)​​
​​​​​
/s/ Jost Fischer​Chairman of the Board​March 30, 2026
Jost Fischer​​​​
​​​​​
/s/ Shelley Thunen​Director​March 30, 2026
Shelley Thunen​​​​
​​​​​
/s/ Robert Palmisano​Director​March 30, 2026
Robert Palmisano​​​​
​​​​​
/s/ Eric Carter​Director​March 30, 2026
Eric Carter​​​​
​​​​​
/s/ Seongsoo Park​Director​March 30, 2026
Seongsoo Park​​​​
​​​​​
/s/ Marc Forth​Director​March 30, 2026
Marc Forth​​​​
​​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.